Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cogent Biosciences, Inc.COGT · Entity 3793 | Director · President and CEO | May 19, 2026 | May 21, 2026 |
| TURMERIC ACQUISITION CORP.TMPM · Entity 139875 | Director | October 15, 2020 | October 15, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cogent Biosciences, Inc.
Report date May 19, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 497,503 |
Reported balance
After 2026-05-19 transaction · row 1
1 source rowRow 1 · 2026-05-19 · Gift · Disposed 160,000 · Balance 497,503 F1: On May 19, 2026, Mr. Robbins transferred 160,000 shares of common stock to a family trust for estate planning purposes. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 160,000 |
Reported balance
After 2026-05-19 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-05-19 · Gift · Acquired 160,000 · Balance 160,000 F1: On May 19, 2026, Mr. Robbins transferred 160,000 shares of common stock to a family trust for estate planning purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 19, 2026, Mr. Robbins transferred 160,000 shares of common stock to a family trust for estate planning purposes.
TURMERIC ACQUISITION CORP.
Report date October 15, 2020 · Filed October 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary Shares, par value $0.0001SEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-10-15 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249099) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249099) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARRAY BIOPHARMA INC
Report date July 30, 2019 · Filed July 30, 2019
Section 16 reporting ended · disclosed 2019-07-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-07-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-07-30 · Disposition to issuer · Disposed 71,022 · Balance 130,542 F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. Row 2 · 2019-07-30 · Disposition to issuer · Disposed 130,542 · Balance 0 F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F3: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.20 · Expires 2025-03-02 | Direct | 0 |
Reported balance
After 2019-07-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-07-30 · Disposition to issuer · Disposed 12,500 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F4: The option provided for vesting in four equal annual installments beginning on March 2, 2016. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.30 · Expires 2025-04-01 | Direct | 0 |
Reported balance
After 2019-07-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-07-30 · Disposition to issuer · Disposed 236,250 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F6: The option provided for vesting in four equal annual installments beginning on April 1, 2016. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2026-04-01 | Direct | 0 |
Reported balance
After 2019-07-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-07-30 · Disposition to issuer · Disposed 236,250 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F7: The option provided for vesting in four equal annual installments beginning on April 1, 2017. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.79 · Expires 2026-12-27 | Direct | 0 |
Reported balance
After 2019-07-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-07-30 · Disposition to issuer · Disposed 313,989 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F8: The option provided for vesting in four equal annual installments beginning on December 26, 2017. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.92 · Expires 2027-12-16 | Direct | 0 |
Reported balance
After 2019-07-30 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-07-30 · Disposition to issuer · Disposed 335,250 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F9: The option provided for vesting in four equal annual installments beginning on December 16, 2018. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.97 · Expires 2028-12-16 | Direct | 0 |
Reported balance
After 2019-07-30 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-07-30 · Disposition to issuer · Disposed 315,750 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F10: The option provided for vesting in four equal annual installments beginning on December 16, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.
F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.
F3: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU.
F4: The option provided for vesting in four equal annual installments beginning on March 2, 2016.
F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option.
F6: The option provided for vesting in four equal annual installments beginning on April 1, 2016.
F7: The option provided for vesting in four equal annual installments beginning on April 1, 2017.
F8: The option provided for vesting in four equal annual installments beginning on December 26, 2017.
F9: The option provided for vesting in four equal annual installments beginning on December 16, 2018.
F10: The option provided for vesting in four equal annual installments beginning on December 16, 2019.
Harpoon Therapeutics, Inc.
Report date March 11, 2024 · Filed March 11, 2024
Section 16 reporting ended · disclosed 2024-03-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-03-11 transaction · row 1
1 source rowRow 1 · 2024-03-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F2: Includes 5,000 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share ("Common Stock"). F3: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding RSU was cancelled and automatically converted into the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (i) the Common Stock Merger Consideration (as defined below) payable with respect to such RSU multiplied by (ii) the total number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, with the number of shares of Company Common Stock subject to any such Company RSU that vests based on the achievement of performance goals determined in accordance with the applicable award agreement. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the "Common Stock Merger Consideration"). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.10 | Direct | 0 |
Reported balance
After 2024-03-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-11 · Disposition to issuer · Disposed 1,016 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F6: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.66 | Direct | 0 |
Reported balance
After 2024-03-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-11 · Disposition to issuer · Disposed 2,300 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F6: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger").
F2: Includes 5,000 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share ("Common Stock").
F3: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding RSU was cancelled and automatically converted into the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (i) the Common Stock Merger Consideration (as defined below) payable with respect to such RSU multiplied by (ii) the total number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, with the number of shares of Company Common Stock subject to any such Company RSU that vests based on the achievement of performance goals determined in accordance with the applicable award agreement.
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the "Common Stock Merger Consideration").
F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the
F6: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2018 Filed Apr 3, 2018 18:48 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Tax withholdingCommon Stock | 8,675 | $16.32 | $141,576.00 |
DisclosureSEC source: 0001562180-18-001801 · primarydocument.xml · nonDerivative · entry 2 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,467 F3 · shares: Represents shares withheld to satisfy tax withholding obligations of the reporting person. Read SEC document |
| April 01, 2018 Filed Apr 3, 2018 18:48 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 9,844 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-001801 · primarydocument.xml · nonDerivative · entry 1 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares issued upon settlement of Restricted Stock Units ("RSUs") granted by the Issuer on April 1, 2016 as a result of the vesting of one fourth of such RSUs. F2 · balance_after: Includes (i) 9,844 unvested Restricted Stock Units ("RSUs") awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs, and (ii) 9,844 shares of common stock issued upon the vesting of these RSU's on April 1, 2018. Read SEC document |
| December 18, 2017 Filed Dec 19, 2017 21:05 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionStock Option (Right to Buy) · Derivative | 87,500 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0001562180-17-003957 · primarydocument.xml · derivative · entry 14 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: The option vested in four equal annual installments beginning on April 1, 2015. Read SEC document |
| December 18, 2017 Filed Dec 19, 2017 21:05 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionStock Option (Right to Buy) · Derivative | 89,634 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0001562180-17-003957 · primarydocument.xml · derivative · entry 13 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 89,634 shares Expires 2023-03-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The option vested in four equal annual installments beginning on July 23, 2014. Read SEC document |
| December 18, 2017 Filed Dec 19, 2017 21:05 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,366 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0001562180-17-003957 · primarydocument.xml · derivative · entry 12 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,366 shares Expires 2023-03-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2017 Filed Dec 19, 2017 21:05 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $5.14 | $0.00 |
DisclosureSEC source: 0001562180-17-003957 · primarydocument.xml · derivative · entry 11 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2022-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The option vested in four equal annual installments beginning on July 23, 2013. Read SEC document |
| December 18, 2017 Filed Dec 19, 2017 21:05 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | SaleCommon Stock | 282,874 | $10.72 | $3,032,409.28 |
DisclosureSEC source: 0001562180-17-003957 · primarydocument.xml · nonDerivative · entry 7 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,298 F5 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported for these shares is the weighted average sale price. Details of actual prices for shares sold are available from the Issuer upon request. Read SEC document |
| December 18, 2017 Filed Dec 19, 2017 21:05 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 87,500 | $4.63 | $405,125.00 |
DisclosureSEC source: 0001562180-17-003957 · primarydocument.xml · nonDerivative · entry 6 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 441,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: Includes 19,687 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs. Read SEC document |
| December 18, 2017 Filed Dec 19, 2017 21:05 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 89,634 | $4.91 | $440,102.94 |
DisclosureSEC source: 0001562180-17-003957 · primarydocument.xml · nonDerivative · entry 5 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,672 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: Includes 19,687 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs. Read SEC document |
| December 18, 2017 Filed Dec 19, 2017 21:05 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 20,366 | $4.91 | $99,997.06 |
DisclosureSEC source: 0001562180-17-003957 · primarydocument.xml · nonDerivative · entry 4 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,038 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: Includes 19,687 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs. Read SEC document |
| December 18, 2017 Filed Dec 19, 2017 21:05 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 200,000 | $5.14 | $1,028,000.00 |
DisclosureSEC source: 0001562180-17-003957 · primarydocument.xml · nonDerivative · entry 3 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,672 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: Includes 19,687 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs. Read SEC document |
| December 16, 2017 Filed Dec 19, 2017 21:05 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantStock Option (Right to Buy) · Derivative | 335,250 | $0.00 Strike: $10.92 | $0.00 |
DisclosureSEC source: 0001562180-17-003957 · primarydocument.xml · derivative · entry 10 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,250 Underlying: Common Stock · 335,250 shares Expires 2027-12-16 F10 · derivative.exercise_date: The option vests in four equal annual installments beginning on December 16, 2018. Read SEC document |
| December 16, 2017 Filed Dec 19, 2017 21:05 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantRestricted Stock Units · Derivative | 55,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003957 · primarydocument.xml · derivative · entry 9 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,875 Underlying: Common Stock · 55,875 shares Expires 2021-12-17 F9 · derivative.exercise_date: Consists of RSUs awarded to the reporting person for no additional cash consideration each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock. The RSUs vest and will be settled in stock in four equal annual installments beginning on December 16, 2018. Read SEC document |
| December 16, 2017 Filed Dec 19, 2017 21:05 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionRestricted Stock Units · Derivative | 13,082 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003957 · primarydocument.xml · derivative · entry 8 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,249 Underlying: Common Stock · 13,082 shares Expires 2020-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The RSUs vested on December 16, 2017. F8 · balance_after: Consists of remaining unvested RSUs awarded to the reporting person for no additional cash consideration on December 16, 2016, which vest in three equal remaining installments beginning December 16, 2018, and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The grant of these RSUs were previously reported on a Table II of a form 4 filed by the reporting person. Read SEC document |
| December 16, 2017 Filed Dec 19, 2017 21:05 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Tax withholdingCommon Stock | 6,094 | $10.92 | $66,546.48 |
DisclosureSEC source: 0001562180-17-003957 · primarydocument.xml · nonDerivative · entry 2 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,672 F3 · shares: Represents shares withheld to satisfy tax withholding obligations of the reporting person. Read SEC document |
| December 16, 2017 Filed Dec 19, 2017 21:05 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 13,082 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003957 · primarydocument.xml · nonDerivative · entry 1 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,766 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares issued upon settlement of Restricted Stock Units ("RSUs") granted by the Issuer on December 27, 2016 as a result of the vesting of one fourth of such RSUs. F2 · balance_after: Includes 19,687 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs. Read SEC document |
| April 01, 2017 Filed Apr 4, 2017 21:42 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionRestricted Stock Units · Derivative | 9,843 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-001464 · primarydocument.xml · derivative · entry 3 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,532 Underlying: Common Stock · 9,843 shares Expires 2020-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares issued on settlement of Restricted Stock Units ("RSUs") granted to the reporting person, of which 3,148 shares were withheld upon vesting to satisfy tax. The grant of these RSUs was previously reported on Table II of a form 4 filed by the reporting person. F4 · derivative.exercise_date: The RSUs vest and will be settled in stock in four equal annual installments beginning April 1, 2017. F5 · balance_after: Consists of unvested RSUs awarded to the reporting person for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The grant of these RSUs was previously reported on Table II of a form 4 filed by the reporting person. Read SEC document |
| April 01, 2017 Filed Apr 4, 2017 21:42 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Tax withholdingCommon Stock | 6,293 | $8.94 | $56,259.42 |
DisclosureSEC source: 0001562180-17-001464 · primarydocument.xml · nonDerivative · entry 2 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,558 F3 · shares: Represents shares withheld to satisfy tax withholding obligations of the reporting person in connection with the vesting of RSUs held by the reporting person. Read SEC document |
| April 01, 2017 Filed Apr 4, 2017 21:42 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 9,843 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-001464 · primarydocument.xml · nonDerivative · entry 1 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,851 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares issued on settlement of Restricted Stock Units ("RSUs") granted to the reporting person, of which 3,148 shares were withheld upon vesting to satisfy tax. The grant of these RSUs was previously reported on Table II of a form 4 filed by the reporting person. F2 · balance_after: Includes 19,688 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs. Read SEC document |
| April 01, 2017 Filed Apr 6, 2017 20:31 UTC Amendment | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Tax withholdingCommon Stock | 9,167 | $8.94 | $81,952.98 |
DisclosureSEC source: 0001562180-17-001485 · primarydocument.xml · nonDerivative · entry 1 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,684 F1 · shares: This amendment to form 4 is being filed to correct number of shares withheld to satisfy the reporting person's tax withholding obligations in connection with the vesting of Restricted Stock Units previously reported on a form 4 by the reporting person. No other information in such form 4 is being amended. Read SEC document |
| December 27, 2016 Filed Dec 29, 2016 17:52 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantStock Option (Right to Buy) · Derivative | 313,989 | $0.00 Strike: $8.79 | $0.00 |
DisclosureSEC source: 0001562180-16-003918 · primarydocument.xml · derivative · entry 2 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,989 Underlying: Common Stock · 313,989 shares Expires 2026-12-27 F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on December 16, 2017. Read SEC document |
| December 27, 2016 Filed Dec 29, 2016 17:52 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantRestricted Stock Units · Derivative | 52,331 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-16-003918 · primarydocument.xml · derivative · entry 1 Robbins Andrew R · CIK 0001590157 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,331 Underlying: Common Stock · 52,331 shares Expires 2020-12-28 F1 · derivative.exercise_date: Consists of RSUs awarded to the reporting person for no additional cash consideration each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock. The RSUs vest and will be settled in stock in four equal annual installments beginning on December 16, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.